Coordinating center for the NCI small cell lung cancer research consortium

摘要 NCI小细胞肺癌（SCLC）协调中心的首要目标是“打破癌症的恶性循环”。 基本知识差距的“僵局”导致30多年来这种致命的恶性肿瘤缺乏进展， 被美国国会和NCI指定为“恶性肿瘤”。我们的U24协调中心 通过促进和促进NCI之间的信息共享、互动和合作研究， 支持研究SCLC的研究人员。在我们最初的五年支持中，该协调中心 显著增加了SCLC研究界的研究进展，通过努力，包括，但不 局限于创建和持续扩展综合临床前和临床组学数据库， 对可用SCLC模型进行集中注释和编目，分发和共享这些模型， 集中的数据分析，集中的联盟网站，互动工作的启动和协调- 此外，本集团亦负责规划及监督年度会议。在这一切中， 协调中心，促进互动式WIPs（通常有来自数十个机构的约100名与会者 包括患者倡导者），通过前所未有的信息和资源共享， 在克服知识差距方面取得了巨大进展，所有这些都记录在大量同行 审查出版物。这一更新申请将继续SCLC的特殊研究势头 联合会通过支持新的倡议，在这一初步成功的基础上再接再厉。这些包括 集中支持基因工程小鼠模型（GEMM）的数据库和比较分析， 和跨联盟开发的患者来源的异种移植模型的多参数表征。 这些额外的资源将直接用于SCLC研究界。作为U24更新的一部分， 鉴于SCLC研究的范围和多样性的显着增长，我们开发了一种新的多PI 结构包括查尔斯鲁丁（MSK），约翰明娜（UTSW），加上两个令人兴奋的年轻SCLC 为SCLC分子和细胞生物学贡献重要新见解的研究人员-特鲁迪 奥利弗（犹他州大学）和劳伦拜尔斯（MDACC）。这四个人都非常活跃， U24活动和他们自己的个人SCLC U 01和R 01研究。这种互补的优势 领导团队涵盖SCLC基础、转化和临床试验研究的所有重要领域。博士 Rudin将继续担任PI联系人，提供行政领导和协调。我们强调 该联盟的产品将通过促进新战略的发展最终造福人类健康 用于疾病预防、早期干预、免疫监视、转移抑制和治疗。

ABSTRACT The overarching goal of the NCI Small Cell Lung Cancer (SCLC) Coordinating Center has been to “break the logjam” of fundamental knowledge gaps resulting in a 30+ year lack of progress on this lethal malignancy that was designated a “recalcitrant cancer” by the US Congress and NCI. Our U24 Coordinating Center has done this by promoting and facilitating information sharing, interaction, and collaborative research among NCI- supported investigators studying SCLC. Over our initial five years of support, this Coordinating Center has significantly increased research progress within the SCLC research community through efforts including, but not limited to, the creation and ongoing expansion of comprehensive preclinical and clinical -omics databases, centralized annotation and cataloging of available SCLC models, distribution and sharing of such models, centralized data analytics, a centralized Consortium website, initiation and coordination of an interactive work- in-progress (“WIPs”) forum as well as planning and oversight of annual meetings. Of all of this, the role of the Coordinating Center in facilitating interactive WIPs (usually with ~100 attendees from dozens of institutions including patient advocates) with unprecedented information and resource sharing, has made possible tremendous progress in overcoming knowledge gaps, all of which are documented in a large number of peer reviewed publications. This renewal application will continue the exceptional research momentum the SCLC Consortium has generated, and build on this initial success through support of new initiatives. These include centralized support for databasing and comparative analysis of genetically-engineered mouse models (GEMMs), and multi-parameter characterization of patient-derived xenograft models developed across the Consortium. These additional resources will be of direct utility to the SCLC research community. As part of the U24 renewal, given the remarkable growth in scope and diversity of SCLC research, we have developed a new multi-PI structure including Charles Rudin (MSK), John Minna (UTSW), with addition of two exciting young SCLC investigators who have contributed important new insights into SCLC molecular and cellular biology - Trudy Oliver (University of Utah), and Lauren Byers (MDACC). All four have been personally very active both in the U24 activities and in their own individual SCLC U01 and R01 research. The complementary strengths of this leadership team cover all of the important areas of SCLC basic, translational, and clinical trials research. Dr. Rudin will continue as contact PI, providing administrative leadership and coordination. We emphasize that the products of the Consortium will ultimately benefit human health through fostering development of novel strategies for disease prevention, early intervention, immune surveillance, metastasis suppression, and therapeutics.